Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan 18;23(1):18.
doi: 10.1186/s13054-019-2315-y.

Vascular endothelial cadherin shedding is more severe in sepsis patients with severe acute kidney injury

Wen-Kuang Yu  1   2   3 , J Brennan McNeil  3 , Nancy E Wickersham  3 , Ciara M Shaver  3 , Julie A Bastarache  3   4   5 , Lorraine B Ware  6   7
Affiliations

Vascular endothelial cadherin shedding is more severe in sepsis patients with severe acute kidney injury

Wen-Kuang Yu et al. Crit Care. .

Abstract

Background: Vascular endothelial cadherin (VE-cadherin) is a membrane protein that is the major component of adherens junctions between endothelial cells. It is crucial for regulating vascular integrity, endothelial permeability, and angiogenesis. During inflammatory processes, VE-cadherin is shed into circulation (sVE-cadherin). Plasma sVE-cadherin is elevated in sepsis, malignancy, autoimmune diseases, and coronary atherosclerosis. However, the relationship between specific organ failures, especially severe acute kidney injury (AKI) defined by requirement for renal replacement therapy (AKI-RRT), and plasma sVE-cadherin levels in severe sepsis has not been well studied.

Methods: The present study is a prospective study of critically ill adults with sepsis and acute respiratory failure (age ≥ 18 years) enrolled in the Validating Acute Lung Injury markers for Diagnosis (VALID) study. Plasma sVE-cadherin was measured at study enrollment. Primary analysis focused on the association between sVE-cadherin levels and the development of AKI, AKI-RRT, other organ dysfunction as defined by Brussels organ failure scores, pulmonary versus non-pulmonary sepsis, acute respiratory distress syndrome (ARDS), and in-hospital mortality.

Results: Of 228 severe sepsis patients included, 80 (35%) developed AKI-RRT. Plasma sVE-cadherin levels at enrollment were significantly higher in patients with AKI-RRT compared with patients without AKI-RRT (p = 0.003). Plasma sVE-cadherin levels by quartile were significantly higher in severe sepsis patients with acute kidney injury stage 3 (p = 0.044) as defined by Kidney Disease Improving Global Outcomes (KDIGO) criteria. Patients with greater than 2 organ failures had higher plasma sVE-cadherin levels than patients with 2 or fewer organ failures (p < 0.001). In a multivariable analysis, plasma sVE-cadherin was independently associated with AKI-RRT (odds ratio 6.44 per log increase in plasma sVE-cadherin, 95% CI 1.126-36.847, p = 0.036). Plasma sVE-cadherin levels were significantly higher in patients with non-pulmonary sepsis compared to pulmonary sepsis (p < 0.001).

Conclusion: Shedding of sVE-cadherin is associated with severe acute kidney injury and with more severe organ dysfunction in patients with sepsis, suggesting that breakdown of endothelial adherens junctions may contribute to the pathogenesis of organ dysfunction in sepsis. Further studies of sVE-cadherin as a biomarker of disease severity in clinical sepsis are needed to better elucidate the role of VE-cadherin shedding in sepsis-induced severe organ dysfunction.

Keywords: Acute kidney injury; Endothelial injury; Renal replacement therapy; Sepsis; Soluble vascular endothelial cadherin.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

The prospective study was approved by Vanderbilt Institutional Review Board (IRB #051065). Informed consent was obtained for sample collection from the patients or surrogates whenever possible; if patients or surrogates were unable to provide consent, the institutional review board granted a waiver of consent due to the minimal risk nature of the study.

Consent for publication

not applicable

Competing interests

The authors declare they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Plasma sVE-cadherin levels were weakly associated with a urine output and b serum creatinine levels on enrolling day. Higher plasma sVE-cadherin levels by quartile were significantly associated with c AKI stage 3 and d the need for renal replacement therapy
Fig. 2
Fig. 2
Higher plasma sVE-cadherin levels by quartile were associated with a hepatic failure on enrolling day, but not with b circulatory failure on enrolling day or c coagulation failure on enrolling day. Organ failures were defined by Brussels organ failure scores [30]. d Plasma sVE-cadherin levels were not associated with the development of ARDS defined by Berlin criteria during the study period [32]. Data in panels a–d were analyzed by linear-by-linear association test. e Plasma sVE-cadherin levels were associated with the number of organ failures on enrolling day. f Plasma sVE-cadherin levels were significantly higher in patients with greater than 2 organ failures compared with patients with 2 or fewer organ failures on enrolling day. Data in panel e and f were summarized as boxplots where box encompasses 25th–75th percentile, error bars encompass 10th–90th percentile, and horizontal line shows median. Data in panels e and f were analyzed by Kruskal-Wallis H test
Fig. 3
Fig. 3
a There was no significant difference in plasma sVE-cadherin levels between patients who died or survived from severe sepsis. b Plasma sVE-cadherin levels were significantly higher in patients with non-pulmonary sepsis compared to those with pulmonary sepsis. Data were summarized as boxplots where box encompasses 25th–75th percentile, error bars encompass 10th–90th percentile, and horizontal line shows median, and groups were compared by Mann-Whitney U test
See this image and copyright information in PMC

Comment in

References

    1. Meyer N, Harhay MO, Small DS, Prescott HC, Bowles KH, Gaieski DF, Mikkelsen ME. Temporal trends in incidence, sepsis-related mortality, and hospital-based acute care after sepsis. Crit Care Med. 2018;46:354–360. doi: 10.1097/CCM.0000000000002872. - DOI - PMC - PubMed
    1. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, Kumar A, Sevransky JE, Sprung CL, Nunnally ME, Rochwerg B, Rubenfeld GD, Angus DC, Annane D, Beale RJ, Bellinghan GJ, Bernard GR, Chiche JD, Coopersmith C, De Backer DP, French CJ, Fujishima S, Gerlach H, Hidalgo JL, Hollenberg SM, Jones AE, Karnad DR, Kleinpell RM, Koh Y, Lisboa TC, Machado FR, Marini JJ, Marshall JC, Mazuski JE, McIntyre LA, McLean AS, Mehta S, Moreno RP, Myburgh J, Navalesi P, Nishida O, Osborn TM, Perner A, Plunkett CM, Ranieri M, Schorr CA, Seckel MA, Seymour CW, Shieh L, Shukri KA, Simpson SQ, Singer M, Thompson BT, Townsend SR, Van der Poll T, Vincent JL, Wiersinga WJ, Zimmerman JL, Dellinger RP. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017;43:304–377. doi: 10.1007/s00134-017-4683-6. - DOI - PubMed
    1. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent JL, Angus DC. The third international consensus definitions for sepsis and septic shock (sepsis-3) JAMA. 2016;315:801–810. doi: 10.1001/jama.2016.0287. - DOI - PMC - PubMed
    1. Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med. 2013;369:840–851. doi: 10.1056/NEJMra1208623. - DOI - PubMed
    1. Ince C, Mayeux PR, Nguyen T, Gomez H, Kellum JA, Ospina-Tascón GA, Hernandez G, Murray P, De Backer D, Workgroup ADQIXIV. The endothelium in sepsis. Shock. 2016;45:259–270. doi: 10.1097/SHK.0000000000000473. - DOI - PMC - PubMed

MeSH terms